{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:03:02Z","timestamp":1761519782618,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.3816\/ccc.2006.n.027","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:05:49Z","timestamp":1221080749000},"page":"114-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Oxaliplatin-Associated Hypersensitivity Reactions: Clinical Presentation and Management"],"prefix":"10.3816","volume":"6","author":[{"given":"Maureen R.","family":"Hewitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2006.n.027_bib1","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1093\/carcin\/17.12.2763","article-title":"In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells","volume":"17","author":"Saris","year":"1996","journal-title":"Carcinogenesis"},{"key":"10.3816\/CCC.2006.n.027_bib2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1124\/mol.54.5.770","article-title":"Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA","volume":"54","author":"Woynarowski","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.3816\/CCC.2006.n.027_bib3","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0006-2952(97)81490-6","article-title":"Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel","volume":"52","author":"Rixe","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.3816\/CCC.2006.n.027_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF00684890","article-title":"Phase I study of oxaliplatin in patients with advanced cancer","volume":"25","author":"Extra","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2006.n.027_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/oxfordjournals.annonc.a010489","article-title":"Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines","volume":"7","author":"Machover","year":"1996","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib6","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/0959-8049(93)90073-O","article-title":"Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate","volume":"29A","author":"Levi","year":"1993","journal-title":"Eur J Cancer"},{"issue":"2 suppl 5","key":"10.3816\/CCC.2006.n.027_bib7","first-page":"13","article-title":"Pharmacokinetics and safety profile of oxaliplatin","volume":"25","author":"Extra","year":"1998","journal-title":"Semin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib8","first-page":"209","article-title":"Oxaliplatin (L-OHP): global safety in 682 patients","volume":"14","author":"Brienza","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1008200825886","article-title":"Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study","volume":"9","author":"Diaz-Rubio","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00000421-199806000-00015","article-title":"Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil","volume":"21","author":"deBraud","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib11","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"deGramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib12","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","article-title":"Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial","volume":"21","author":"Rothenberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluororuacil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib14","first-page":"253","article-title":"Oxaliplatin\/5-FU\/LV in adjuvant colon cancer: results of the international randomized MOSAIC trial","volume":"22","author":"de Gramont","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"16 suppl","key":"10.3816\/CCC.2006.n.027_bib15","first-page":"1s","article-title":"High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200","volume":"23","author":"Giantonio","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CCC.2006.n.027_bib16","first-page":"158s","article-title":"The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in firstline treatment of metastatic colorectal cancer (MCC). A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"24","author":"Borner","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib17","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1200\/JCO.2002.20.6.1512","article-title":"Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study","volume":"20","author":"Louvet","year":"2002","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CCC.2006.n.027_bib18","first-page":"182s","article-title":"Randomised multicentre phase III study comparing capacitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: the REAL 2 trial","volume":"24","author":"Cunningham","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib19","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2002.07.056","article-title":"Acute oxaliplatin-induced peripheral nerve hyperexcitability","volume":"20","author":"Wilson","year":"2002","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CCC.2006.n.027_bib20","first-page":"154s","article-title":"Polymorphism in sodiumchannel alpha 1-subunit (SCN1A) predicts response, TTP, survival, and toxicity in patients with metastatic colorectal cancer treated with 5-FU\/oxaliplatin","volume":"24","author":"Nagashima","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00689458","article-title":"Hypersensitivity and cross reactivity to cisplatin and analogues","volume":"35","author":"Shlebak","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2006.n.027_bib22","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1385\/CRIAI:24:3:253","article-title":"Hypersensitivity reactions to chemotherapeutic drugs","volume":"24","author":"Shepherd","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.3816\/CCC.2006.n.027_bib24","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/cncr.11379","article-title":"Hypersensitivity and idiosyncratic reactions to oxaliplatin","volume":"97","author":"Thomas","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CCC.2006.n.027_bib25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.bjc.6601155","article-title":"Hypersensitivity reactions related to oxaliplatin (OHP)","volume":"89","author":"Brandi","year":"2003","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2006.n.027_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdj042","article-title":"Hypersensitivity reactions to oxaliplatin: experience in a single institute","volume":"17","author":"Siu","year":"2006","journal-title":"Ann Oncology"},{"key":"10.3816\/CCC.2006.n.027_bib27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1006\/gyno.2001.6331","article-title":"Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies","volume":"82","author":"Robinson","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib28","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.2002.20.4.1146","article-title":"Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule","volume":"20","author":"Meyer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib29","doi-asserted-by":"crossref","unstructured":"Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000-1005.","DOI":"10.1016\/S0959-8049(01)00068-5"},{"key":"10.3816\/CCC.2006.n.027_bib30","first-page":"236","article-title":"Severe anaphylactic reaction to oxaliplatin [letter]","volume":"13","author":"Alliot","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.027_bib32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0091-6749(96)70134-3","article-title":"A modified, prolonged desensitization protocol in carboplatin allergy","volume":"98","author":"Goldberg","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.3816\/CCC.2006.n.027_bib33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1634\/theoncologist.9-5-546","article-title":"Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol","volume":"9","author":"Gammon","year":"2004","journal-title":"Oncologist"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811702511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811702511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:59:20Z","timestamp":1761519560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811702511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S1533002811702511"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2006.n.027","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxaliplatin-Associated Hypersensitivity Reactions: Clinical Presentation and Management","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2006.n.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}